Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

738 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial.
Graham MA, Senan S, Robin H Jr, Eckhardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, von Roemeling R, Workman P. Graham MA, et al. Among authors: kaye sb. Cancer Chemother Pharmacol. 1997;40(1):1-10. doi: 10.1007/s002800050617. Cancer Chemother Pharmacol. 1997. PMID: 9137522 Clinical Trial.
A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate.
McDonald AC, Vasey PA, Adams L, Walling J, Woodworth JR, Abrahams T, McCarthy S, Bailey NP, Siddiqui N, Lind MJ, Calvert AH, Twelves CJ, Cassidy J, Kaye SB. McDonald AC, et al. Among authors: kaye sb. Clin Cancer Res. 1998 Mar;4(3):605-10. Clin Cancer Res. 1998. PMID: 9533527 Clinical Trial.
Phase I and pharmacokinetic study of rhizoxin.
Bissett D, Graham MA, Setanoians A, Chadwick GA, Wilson P, Koier I, Henrar R, Schwartsmann G, Cassidy J, Kaye SB, et al. Bissett D, et al. Among authors: kaye sb. Cancer Res. 1992 May 15;52(10):2894-8. Cancer Res. 1992. PMID: 1581905 Clinical Trial.
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.
Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J. Vasey PA, et al. Among authors: kaye sb. Clin Cancer Res. 1999 Jan;5(1):83-94. Clin Cancer Res. 1999. PMID: 9918206 Clinical Trial.
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.
Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP, Caponigro F, Graf P, Dutreix C, Blackie R, Kaye SB, Ganesan TS, Talbot DC, Harris AL, Twelves C. Propper DJ, et al. Among authors: kaye sb. J Clin Oncol. 2001 Mar 1;19(5):1485-92. doi: 10.1200/JCO.2001.19.5.1485. J Clin Oncol. 2001. PMID: 11230495 Clinical Trial.
738 results